Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes

By Ray Joshua A.   Boye Kristina S.   Yurgin Nicole   Valentine William J.   Roze Stéphane   McKendrick Jan   Tucker Daniel M. D.   Foos Volker   Palmer Andrew J.  

Current Medical Research and Opinion, Vol. 23, Iss. 3, 2007-03 ,pp. : 609-622

Informa Healthcare

Access to resources Recommend Favorite

Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes

By Levin Philip   Wei Wenhui   Wang Li   Pan Chunshen   Douglas Damon   Baser Onur  

Current Medical Research and Opinion, Vol. 28, Iss. 3, 2012-03 ,pp. : 439-446

Informa Healthcare

Access to resources Recommend Favorite

Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine*

By Fabunmi Rosalind   Nielsen Loretta L.   Quimbo Ralph   Schroeder Brock   Misurski Derek   Wintle Matthew   Wade Ron  

Current Medical Research and Opinion, Vol. 25, Iss. 3, 2009-03 ,pp. : 777-786

Informa Healthcare

Access to resources Recommend Favorite

The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m 2 in Spain

By Fonseca Tiago  

Journal of Medical Economics, Vol. 16, Iss. 7, 2013-07 ,pp. : 926-938

Informa Healthcare

Access to resources Recommend Favorite

Impaired first-phase insulin response predicts postprandial blood glucose increment in patients with recently diagnosed type 2 diabetes

By Gredal C.   Rosenfalck A. M.   Dejgaard A.   Hilsted J.  

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 67, Iss. 3, 2007-01 ,pp. : 327-336

Informa Healthcare

Access to resources Recommend Favorite